GGrantIndex
← Leaderboards

Venatorx Pharmaceuticals, Inc.

Malvern, PA

Compare ↔
$169,496,633
Total funding
29
Grants

Funding over time

peak $18M · FY2010–25
$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$169,496,633 · 29

By mechanism

N01$102,058,401 · 3
R01$31,384,925 · 5
R44$29,462,888 · 10
R43$6,590,419 · 11

Investigators at Venatorx Pharmaceuticals, Inc.

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Tsuyoshi Uehara$2,000,0001 gr

Emerging Leaders

6–10 yrs in

1Steven Armen Boyd$13,685,5442 gr2Denis Marc Daigle$7,512,5301 gr

All-Time

Most funded here, all years

1Steven Armen Boyd$13,685,5442 gr2Luigi Xerri$11,437,6187 gr3Denis Marc Daigle$7,512,5301 gr4Bin Liu$3,147,0002 gr5Tsuyoshi Uehara$2,000,0001 gr6Guo-Hua Chu$599,2001 gr7Randy Jackson$150,0001 gr

Largest grants

Development of Therapeutics for Biodefense and Emerging Infectious Diseases$9,756,893
N01 · FY2019 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$9,407,873
N01 · FY2024 · AI
Development of Therapeutic Medical Countermeasures$9,361,587
N01 · FY2015 · AI
Development of Therapeutics for Biodefense and Emerging Infectious Diseases$9,174,369
N01 · FY2017 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$7,440,148
N01 · FY2022 · AI
Development of Therapeutics for Biodefense and Emerging Infectious Diseases$7,098,583
N01 · FY2016 · AI
Development of Therapeutics for Biodefense and Emerging Infectious Diseases$6,803,649
N01 · FY2018 · AI
Development of Therapeutic Medical Countermeasures$5,107,697
N01 · FY2013 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$4,711,879
N01 · FY2023 · AI
Development of Therapeutics for Biodefense and Emerging Infectious Diseases$4,218,337
N01 · FY2021 · AI
Development of Therapeutics for Antimicrobial Resistant Pathogens$3,440,594
N01 · FY2023 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$3,229,128
N01 · FY2020 · AI
Development of Therapeutics for Biodefense and Emerging Infectious Diseases$3,082,188
N01 · FY2020 · AI
Development of Therapeutics for Biodefense and Emerging Infectious Diseases$2,538,994
N01 · FY2019 · AI
Development of Therapeutics for Biodefense and Emerging Infectious Diseases$2,284,288
N01 · FY2022 · AI
Development of Therapeutic Medical Countermeasures$2,057,591
N01 · FY2018 · AI
Development of Therapeutic Medical Countermeasures$2,034,475
N01 · FY2017 · AI
Development of Therapeutic Medical Countermeasures$1,975,628
N01 · FY2014 · AI
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library$1,853,400
R01 · FY2018 · AI
Development of Therapeutic Medical Countermeasures$1,798,159
N01 · FY2016 · AI